NASDAQ:CDT

CDT Equity Q3 2025 Earnings Results & Report

CDT Equity logo
$0.34 -0.03 (-8.49%)
As of 03:04 PM Eastern
This is a fair market value price provided by Massive. Learn more.

CDT Equity reported Q3 2025 earnings on November 13, 2025. The company reported EPS of -$1,645,000.00.

Earnings Announcement Details

Quarter
Q3 2025
Time
After Market Closes

CDT Equity EPS Results

Actual EPS
-$1,645,000.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CDT Equity Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

CDT Equity Q3 2025 Earnings FAQ

CDT Equity (NASDAQ:CDT) reported earnings of -$1,645,000.00 per share for Q3 2025. The report was announced on Thursday, November 13, 2025.

CDT Equity Earnings Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
CDT Equity Announces 1-for-20 Reverse Stock Split
See More CDT Equity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CDT Equity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CDT Equity and other key companies, straight to your email.

About CDT Equity

CDT Equity (NASDAQ:CDT) (NASDAQ: CDT) is associated with the former Conduit Pharmaceuticals, a biotechnology company focused on developing drug candidates for diseases with unmet medical needs.

Conduit’s historical pipeline included compounds licensed from AstraZeneca, with research directed toward areas including inflammation and autoimmune disease. The company’s approach was to advance existing drug candidates rather than discover medicines entirely from scratch.

Conduit had operations and a corporate presence in the United Kingdom and the United States. Because the company’s name and business status have changed, its historical biotechnology activities may not fully describe CDT Equity’s current operations.

View CDT Equity Profile